Justin Balko
Faculty Member
Last active: 4/6/2017

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS (2017) Mol Cancer Res 15(3): 259-268
    › Primary publication · 28039357 (PubMed) · PMC5334148 (PubMed Central)
  2. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ (2016) N Engl J Med 375(18): 1749-1755
    › Primary publication · 27806233 (PubMed) · PMC5247797 (PubMed Central)
  3. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM (2016) Cancer Immunol Res 4(11): 959-967
    › Primary publication · 27671167 (PubMed) · PMC5134329 (PubMed Central)
  4. Maybe we don't know JAK? Schwarz LJ, Balko JM (2016) Mol Cell Oncol 3(4): e1192713
    › Primary publication · 27652332 (PubMed) · PMC4972112 (PubMed Central)
  5. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Nat Rev Clin Oncol 13(11): 674-690
    › Primary publication · 27184417 (PubMed)
  6. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL (2017) Clin Cancer Res 23(1): 26-34
    › Primary publication · 27126994 (PubMed) · PMC5085926 (PubMed Central)
  7. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko JM, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE (2016) Pigment Cell Melanoma Res 29(4): 470-3
    › Primary publication · 27089234 (PubMed)
  8. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL (2016) Sci Transl Med 8(334): 334ra53
    › Primary publication · 27075627 (PubMed) · PMC5256931 (PubMed Central)
  9. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
    › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)
  10. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J (2016) Cancer Res 76(2): 305-18
    › Primary publication · 26744526 (PubMed) · PMC4715957 (PubMed Central)
  11. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM (2016) Clin Cancer Res 22(6): 1499-509
    › Primary publication · 26515496 (PubMed) · PMC4794351 (PubMed Central)
  12. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL (2015) Cancer Res 75(2): 405-14
    › Primary publication · 25480943 (PubMed) · PMC4297507 (PubMed Central)
  13. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL (2014) Hematol Oncol Stem Cell Ther 7(4): 142-8
    › Primary publication · 25467032 (PubMed)
  14. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL (2014) J Clin Invest 124(12): 5490-502
    › Primary publication · 25401474 (PubMed) · PMC4348968 (PubMed Central)
  15. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW (2015) Oncogene 34(30): 3968-76
    › Primary publication · 25284585 (PubMed) · PMC4387124 (PubMed Central)
  16. Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, Bao PP, Cai H, Zhao Z, Balko J, Zheng W, Lu W, Shu XO (2014) Breast Cancer Res Treat 148(1): 211-20
    › Primary publication · 25281216 (PubMed) · PMC4200532 (PubMed Central)
  17. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS (2014) J Clin Invest 124(11): 4737-52
    › Primary publication · 25250573 (PubMed) · PMC4347249 (PubMed Central)
  18. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA (2014) Clin Cancer Res 20(7): 1757-67
    › Primary publication · 24398047 (PubMed) · PMC3998833 (PubMed Central)
  19. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
  20. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS (2013) J Clin Invest 123(10): 4329-43
    › Primary publication · 23999432 (PubMed) · PMC3784526 (PubMed Central)
  21. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL (2013) Cancer Res 73(20): 6346-58
    › Primary publication · 23966295 (PubMed) · PMC4090144 (PubMed Central)
  22. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Proc Natl Acad Sci U S A 110(35): 14372-7
    › Primary publication · 23940356 (PubMed) · PMC3761610 (PubMed Central)
  23. The genomic map of breast cancer: which roads lead to better targeted therapies? Balko JM, Stricker TP, Arteaga CL (2013) Breast Cancer Res 15(4): 209
    › Primary publication · 23905624 (PubMed) · PMC3979080 (PubMed Central)
  24. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB (2013) Clin Cancer Res 19(13): 3703-13
    › Primary publication · 23697991 (PubMed) · PMC3727144 (PubMed Central)
  25. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Cancer Res 73(13): 4075-85
    › Primary publication · 23633485 (PubMed) · PMC3702683 (PubMed Central)
  26. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) J Clin Invest 123(3): 1348-58
    › Primary publication · 23391723 (PubMed) · PMC3582135 (PubMed Central)
  27. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL (2012) Mol Cancer Ther 11(10): 2301-5
    › Primary publication · 22879364 (PubMed) · PMC3682668 (PubMed Central)
  28. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL (2012) Nat Med 18(7): 1052-9
    › Primary publication · 22683778 (PubMed) · PMC3693569 (PubMed Central)
  29. Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms. Balko JM, Arteaga CL (2012) Mol Diagn Ther 16(1): 1-6
    › Primary publication · 22339590 (PubMed)
  30. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS (2012) Proc Natl Acad Sci U S A 109(1): 221-6
    › Primary publication · 22178756 (PubMed) · PMC3252958 (PubMed Central)
  31. Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling. Oh YT, Yue P, Zhou W, Balko JM, Black EP, Owonikoko TK, Khuri FR, Sun SY (2012) J Biol Chem 287(1): 257-67
    › Primary publication · 22065586 (PubMed) · PMC3249076 (PubMed Central)
  32. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) Cancer Discov 1(4): 338-51
    › Primary publication · 22049316 (PubMed) · PMC3204388 (PubMed Central)
  33. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, Black EP (2012) Br J Cancer 106(1): 148-56
    › Primary publication · 22045191 (PubMed) · PMC3251842 (PubMed Central)
  34. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Miller TW, Balko JM, Arteaga CL (2011) J Clin Oncol 29(33): 4452-61
    › Primary publication · 22010023 (PubMed) · PMC3221526 (PubMed Central)
  35. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL (2011) Cancer Res 71(21): 6773-84
    › Primary publication · 21908557 (PubMed) · PMC3206206 (PubMed Central)
  36. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL (2011) Clin Cancer Res 17(7): 2024-34
    › Primary publication · 21346144 (PubMed) · PMC3221728 (PubMed Central)
  37. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL (2011) Cancer Res 71(5): 1871-82
    › Primary publication · 21324925 (PubMed) · PMC3221734 (PubMed Central)
  38. Do the genes tell us the path of most resistance? Balko JM, Black EP (2011) Cancer Biol Ther 11(2): 213-5
    › Primary publication · 21263213 (PubMed)
  39. Dead-box or black-box: is DDX1 a potential biomarker in breast cancer? Balko JM, Arteaga CL (2011) Breast Cancer Res Treat 127(1): 65-7
    › Primary publication · 20694745 (PubMed)
  40. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling. Britson JS, Barton F, Balko JM, Black EP (2009) Biochem Biophys Res Commun 390(3): 849-54
    › Primary publication · 19836351 (PubMed)
  41. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB (2009) Int J Oncol 35(2): 337-45
    › Primary publication · 19578748 (PubMed) · PMC4098131 (PubMed Central)
  42. A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. Balko JM, Black EP (2009) BMC Cancer : 145
    › Primary publication · 19439077 (PubMed) · PMC2687459 (PubMed Central)
  43. Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, Romond E (2009) AAPS PharmSciTech 10(2): 410-7
    › Primary publication · 19381833 (PubMed) · PMC2690785 (PubMed Central)
  44. MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. Balko JM, Jones BR, Coakley VL, Black EP (2009) Cancer Biol Ther 8(6): 522-30
    › Primary publication · 19305165 (PubMed)
  45. Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature. Balko JM, Black EP (2009) Cancer Biol Ther 8(2): 167-73
    › Primary publication · 19029813 (PubMed)
  46. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP (2006) BMC Genomics : 289
    › Primary publication · 17096850 (PubMed) · PMC1660550 (PubMed Central)